Living Cell Technologies closes IPO
Friday, 27 August, 2004
Living Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
The company is expected to move from the Newcastle stock exchange (NSX) to the ASX on September 1, and has been suspended from trading on the NSX in preparation.
"LCT is a unique biotechnology company with an international infrastructure, significant scientific and commercial potential and a clear path to market. Transferring to the ASX is a significant and strategic step in our development and the keen interest in our capital raising not only validates our hard work to date but will underscore continued success in further developing our unique technology," said CEO David Collinson in a statement.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
